Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) EBIT (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed EBIT for 12 consecutive years, with -$26.5 million as the latest value for Q1 2026.

  • For Q1 2026, EBIT fell 21.06% year-over-year to -$26.5 million; the TTM value through Mar 2026 reached -$148.0 million, down 182.27%, while the annual FY2025 figure was -$143.4 million, 226.69% down from the prior year.
  • EBIT hit -$26.5 million in Q1 2026 for Cartesian Therapeutics, up from -$78.6 million in the prior quarter.
  • Across five years, EBIT topped out at $13.9 million in Q2 2022 and bottomed at -$78.6 million in Q4 2025.
  • Average EBIT over 5 years is -$16.8 million, with a median of -$18.4 million recorded in 2023.
  • Year-over-year, EBIT skyrocketed 2966.37% in 2022 and then crashed 717.07% in 2023.
  • Cartesian Therapeutics' EBIT stood at -$8.5 million in 2022, then crashed by 327.64% to -$36.3 million in 2023, then increased by 26.43% to -$26.7 million in 2024, then plummeted by 194.19% to -$78.6 million in 2025, then skyrocketed by 66.3% to -$26.5 million in 2026.
  • According to Business Quant data, EBIT over the past three periods came in at -$26.5 million, -$78.6 million, and -$21.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.